share_log

Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $42

Moomoo 24/7 ·  Mar 14 07:54

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and raises the price target from $26 to $42.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment